Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd in HER2-Low Breast Cancer With Brain Metastases
NCT06048718Phase 2Active, not recruiting
- Sponsor
- MEDSIR
- Start
- Jun 2024
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in breast cancer, sponsored by MEDSIR. Started Jun 2024; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06048718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06048718.